Difference between revisions of "Part:BBa K4165150"

Line 8: Line 8:
 
===Usage and Biology===
 
===Usage and Biology===
 
This part is derived from D-enantiomeric peptide its amino acid sequence is APTLLRLHSLGA, that can bind to PHF seed (VQIVYK), its half maximal concentration for tau fibril formation inhibition is 139.6 μM. In addition, it has low cell penetration ability.
 
This part is derived from D-enantiomeric peptide its amino acid sequence is APTLLRLHSLGA, that can bind to PHF seed (VQIVYK), its half maximal concentration for tau fibril formation inhibition is 139.6 μM. In addition, it has low cell penetration ability.
 
<!-- -->
 
<span class='h3bb'>Sequence and Features</span>
 
<partinfo>BBa_K4165150 SequenceAndFeatures</partinfo>
 
 
  
  
Line 34: Line 29:
 
<p><img src="https://static.igem.wiki/teams/4165/wiki/parts-registry/apt-qa.png" style="margin-left:75px;" alt="" width="800" /></p>
 
<p><img src="https://static.igem.wiki/teams/4165/wiki/parts-registry/apt-qa.png" style="margin-left:75px;" alt="" width="800" /></p>
 
</html>
 
</html>
 +
 +
 +
<!-- -->
 +
<span class='h3bb'> <p style=" font-weight: bold; font-size:17px;"> Sequence and Features</p> </span>
 +
<partinfo>BBa_K4165150 SequenceAndFeatures</partinfo>
 +
  
  

Revision as of 13:37, 6 October 2022


APT Peptide

Tau binding peptide targeting the PHF seed of Tau


Usage and Biology

This part is derived from D-enantiomeric peptide its amino acid sequence is APTLLRLHSLGA, that can bind to PHF seed (VQIVYK), its half maximal concentration for tau fibril formation inhibition is 139.6 μM. In addition, it has low cell penetration ability.


Dry Lab

Modeling

APT were modeled by AlphaFold2, Apptest, ITASSER and RosettaFold. best model is obtained from AlphaFold2 and the model is shown below


                            Figure 1.: Predicted 3D structure of Synthetic peptide APT.

Table 1: Quality assessment parameters of TLKIVW model.


Sequence and Features


Assembly Compatibility:
  • 10
    COMPATIBLE WITH RFC[10]
  • 12
    COMPATIBLE WITH RFC[12]
  • 21
    COMPATIBLE WITH RFC[21]
  • 23
    COMPATIBLE WITH RFC[23]
  • 25
    COMPATIBLE WITH RFC[25]
  • 1000
    COMPATIBLE WITH RFC[1000]


References

1. Dammers, C., Yolcu, D., Kukuk, L., Willbold, D., Pickhardt, M., Mandelkow, E., ... & Funke, S. A. (2016). Selection and Characterization of Tau Binding ᴅ-Enantiomeric Peptides with Potential for Therapy of Alzheimer Disease. PLoS One, 11(12), e0167432.